ProLynx Issued Key Patent for Using Releasable Linkers on Insoluble Carriers
February 04, 2015 10:04 ET
|
ProLynx Inc.
SAN FRANCISCO, Feb. 4, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of a novel platform for half-life extension of injectable drugs – peptides, proteins...
ProLynx Awarded NSF Phase II Grant for Controlled Drug Release From and Degradation of Hydrogels
November 13, 2014 10:00 ET
|
ProLynx Inc.
SAN FRANCISCO, Nov. 13, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs, today...
ProLynx Issues U.S. Patent Covering Controlled Release Drug Conjugates
June 17, 2014 16:00 ET
|
ProLynx Inc.
SAN FRANCISCO, June 17, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs, today...
RxGen and ProLynx Present Data on Ocular Delivery Platform
May 13, 2014 10:00 ET
|
ProLynx Inc.
SAN FRANCISCO, May 13, 2014 (GLOBE NEWSWIRE) -- RxGen and ProLynx LLC, presented primate study data showing that polyethylene glycols (PEGs) are appropriate supports to extend ocular pharmacokinetics...
ProLynx Issues U.S. Patent Covering Controlled Drug Release From Dendrimers
April 22, 2014 16:00 ET
|
ProLynx Inc.
SAN FRANCISCO, April 22, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs today...
ProLynx Publishes Results of Ultralong Half-Life PEG-SN38 Pro-Drug With Lower Intestinal Toxicity
March 27, 2014 16:00 ET
|
ProLynx Inc.
SAN FRANCISCO, March 27, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC today announced a publication in the Journal of Medicinal Chemistry on macromolecular pro-drugs that provide the irinotecan...
ProLynx Issues U.S. Patent Covering Beta-Eliminative Linkers
March 25, 2014 15:24 ET
|
ProLynx Inc.
SAN FRANCISCO, March 25, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs –...